Repligen (NASDAQ:RGEN) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Repligen (NASDAQ:RGEN) from a hold rating to a buy rating in a research note published on Saturday.

Other equities analysts also recently issued reports about the stock. Barclays boosted their target price on shares of Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Weiss Ratings downgraded shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, January 30th. Wells Fargo & Company upped their target price on shares of Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, December 15th. UBS Group lifted their price target on Repligen from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Finally, Canaccord Genuity Group boosted their price target on Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and an average price target of $179.62.

Repligen Stock Performance

Shares of RGEN opened at $142.18 on Friday. The firm has a fifty day simple moving average of $161.90 and a 200 day simple moving average of $145.05. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26. Repligen has a 12 month low of $102.96 and a 12 month high of $175.77. The stock has a market capitalization of $8.00 billion, a price-to-earnings ratio of 7,112.56, a PEG ratio of 2.58 and a beta of 1.13.

Insider Transactions at Repligen

In other Repligen news, Director Anthony Hunt sold 25,000 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $156.88, for a total value of $3,922,000.00. Following the transaction, the director directly owned 100,743 shares of the company’s stock, valued at $15,804,561.84. This represents a 19.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO James Bylund sold 2,191 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the transaction, the chief operating officer owned 21,520 shares in the company, valued at $3,254,039.20. The trade was a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 49,657 shares of company stock worth $7,721,077. Company insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in RGEN. AQR Capital Management LLC acquired a new stake in shares of Repligen in the first quarter valued at approximately $262,000. Jones Financial Companies Lllp grew its holdings in shares of Repligen by 3,850.6% during the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock worth $814,000 after purchasing an additional 6,238 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Repligen by 16.8% in the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock worth $18,067,000 after purchasing an additional 20,375 shares during the period. KLP Kapitalforvaltning AS raised its position in shares of Repligen by 5.8% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 11,000 shares of the biotechnology company’s stock valued at $1,368,000 after buying an additional 600 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its holdings in shares of Repligen by 0.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 14,700 shares of the biotechnology company’s stock worth $1,828,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.